Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bepotastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 6/20 | 0.55 |
| ▸ | DRD2 | P14416 | 10/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bepotastine SCHEMBL30200949 | 1.00 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL5151702 | 1.00 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL726880 | 1.00 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL29459 | 1.00 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2806225 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2808049 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2807641 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2803678 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| SCHEMBL28391952 | 0.96 | BCHE (0.56) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2804852 | 0.95 | BCHE (0.54) | BCHEDRD2NPC1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3179982-B1 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | SUN PHARMA ADVANCED RES CO LTD (IN) | 2023-07-19 | — | — | EP | claimed |
| CN-115023418-A | Bis-aminoquinoline and nanoformulation for cancer treatment | 加利福尼亚大学董事会 | 2022-09-06 | — | — | CN | claimed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12403094-B2 | Rheological solid oral composition | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4119231-B1 | LIQUID DISPENSER | APTAR RADOLFZELL GMBH (DE) | 2025-01-15 | — | — | EP | disclosed |
| CN-113072486-B | Amino alcohol-boron-binaphthol complex and preparation method of optically active amino alcohol derivative using same | 分子与物质株式会社 | 2024-10-11 | — | — | CN | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4119231-A1 | LIQUID DISPENSER | Aptar Radolfzell GmbH (DE) | 2023-01-18 | — | — | EP | disclosed |
| CN-115607521-A | Compositions and methods for treating anemia | 阿克比治疗有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-111032646-B | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022206451-A1 | TARGETED FERRITIN CAGE NANO-CARRIER CO-LOADING HYDROPHILIC/HYDROPHOBIC DRUGS AND USE THEREOF | 南京纳么美科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-108138187-B | Method for increasing replication of circular DNA molecules | 库瑞瓦格房地产有限公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022070289-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022070288-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022070287-A1 | MACROCYCLE COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | HRH1 2461/4885BCHE 3532/4885DRD2 2444/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | HRH1 4535/4885BCHE 2986/4885DRD2 2909/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | HRH1 4220/4885BCHE 3518/4885DRD2 2795/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | HRH1 2748/4885BCHE 3262/4885DRD2 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.